Frequently Asked Questions

Mounjaro is the brand name for tirzepatide, made by Eli Lilly and distributed in South Africa by Aspen Pharmacare. It is a once weekly subcutaneous injection, a dual GIP and GLP-1 receptor agonist, registered for type 2 diabetes and chronic weight management.

According to IQVIA sales data confirmed by Aspen, Mounjaro became South Africa's highest selling pharmaceutical product in November 2025. Strong clinical results, expanded indication, and high demand for weight management treatments drove growth.

Same molecule. Tirzepatide is the active ingredient. Mounjaro is the brand name. In the United States, the same molecule for weight management is also sold under the brand Zepbound. In SA both indications use the Mounjaro brand.

Adults with type 2 diabetes, or adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight related condition. Not approved for adolescents in SA. Full eligibility.

Not in South Africa. Wegovy (semaglutide) is the only GLP-1 medication SAHPRA approved for adolescents aged 12 and older.

No. Stop the medication at least one month before trying to conceive. Tirzepatide is contraindicated in pregnancy and breastfeeding.

It mimics two gut hormones, GIP and GLP-1. The dual action reduces appetite, slows gastric emptying, improves insulin response, and produces stronger trial results than older single-receptor GLP-1 medications. The mechanism explained.

Mounjaro acts on two hormone receptors (GIP and GLP-1) versus Wegovy's one. In head to head trials this produces larger average effects on weight and blood sugar. The comparison.

Almost always 2.5 mg weekly for the first four weeks. This is a starting dose, not a therapeutic dose. The titration steps up every four weeks. Full dose schedule.

15 mg weekly is the maximum approved dose. Many people respond well at 7.5 mg or 10 mg and stay there.

If less than four days late, take it as soon as you remember. If four or more days late, skip and take your next dose on your usual day. Do not double up.

Nausea, vomiting, diarrhoea, constipation, indigestion, abdominal discomfort, fatigue, headache, and reduced appetite. Mostly gastrointestinal, most prominent early and after dose increases. Full safety profile.

Rare but recognised risk. Severe persistent abdominal pain radiating to the back warrants urgent assessment.

Some hair shedding is reported, generally related to significant weight loss rather than the medication directly. It is temporary and resolves as weight stabilises.

R3,400 to R5,500+ per month depending on dose. Starting doses cheaper, maximum dose more expensive. Detailed cost analysis.

For type 2 diabetes, often yes (diabetes is on the PMB Chronic Disease List). For weight management, variable cover from medical savings accounts. Check directly.

Any SAPC registered SA pharmacy. Major retailers (Clicks, Dis-Chem, Alpha Pharm), independent pharmacies, and online dispensing pharmacies. Confirm stock before paying for the consultation.

Yes. Tirzepatide reduces oral contraceptive absorption. Backup contraception for four weeks after starting and after each dose increase, or switch to a non-oral method. More on this.

For many women with PCOS and insulin resistance, weight reduction and improved insulin sensitivity (both effects of tirzepatide) improve PCOS symptoms.

Depends on what you are optimising for. Mounjaro for stronger weight loss or diabetes. Wegovy for cost, adolescent use, established cardiovascular disease, or no oral contraceptive interaction. Full comparison.

Yes, under medical supervision. The new medication starts at its lowest dose and titrates up. The treating doctor manages the switch.

Light to moderate drinking is usually fine. Heavy drinking increases nausea and pancreatitis risk. Many people find tolerance for alcohol decreases on tirzepatide.

Yes, and recommended. Resistance training and adequate protein during weight loss protect lean mass. Cardio supports cardiovascular health.

Stop the medication immediately and consult your treating doctor. Tirzepatide is not used in pregnancy.

Appetite returns and weight tends to come back over time. SURMOUNT-4 trial showed substantial regain after stopping. The medication is intended as long term treatment.

That depends on your situation. Many people use it long term, similar to medication for blood pressure or cholesterol. The treating doctor reviews periodically.